Aurinia Pharmaceuticals Inc (AUPH)

[nferna]

Kiwi,

Increase in eGFR is not an efficacy endpoint in Aurinia's LN trials, nor was it an endpoint in BLISS-LN and it is not an endpoint in the KZR trial either.

As we all know, VOC is not meant to replace SOC, it is given in addition to SOC.

Apologies for jamming up the board with this discussion of things we all know already.

I won't reply further to this user.